Send to

Choose Destination
MMWR Morb Mortal Wkly Rep. 2012 Aug 31;61(34):671-7.

National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011.

Erratum in

  • MMWR Morb Mortal Wkly Rep. 2012 Oct 19;61(41):844.


Since 2005, the Advisory Committee on Immunization Practices (ACIP) has expanded the routine adolescent vaccination schedule with administration of the following vaccines at ages 11 or 12 years: meningococcal conjugate (MenACWY), 2 doses; tetanus, diphtheria, acellular pertussis (Tdap), 1 dose; human papillomavirus (HPV), 3 doses; and influenza, 1 dose annually. To assess vaccination coverage among adolescents aged 13-17 years, CDC analyzed data from the National Immunization Survey-Teen (NIS-Teen). This report summarizes the results of that assessment, which indicated that, from 2010 to 2011, vaccination coverage increased for ≥1 dose Tdap on or after age 10 years (from 68.7% to 78.2%), ≥1 dose MenACWY (from 62.7% to 70.5%), and, among females, for ≥1 dose of HPV (from 48.7% to 53.0%) and ≥3 doses of HPV (from 32.0 to 34.8%). Vaccination coverage varied widely among states. Interventions that increase adolescent vaccination coverage include strong recommendations from health-care providers, urging consideration of every health visit as an opportunity for vaccination, reducing out-of-pocket costs, and using reminder/recall systems. Despite increasing adolescent vaccination coverage, the percentage point increase in ≥1 dose HPV coverage among adolescent females was less than half that of the increase in ≥1 dose of Tdap or MenACWY. The causes of lower coverage with HPV vaccine are multifactorial; addressing missed opportunities for vaccination, as well as continued evaluation of vaccination-promoting initiatives, is needed to protect adolescents against HPV-related cancers.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for CDC - Morbidity and Mortality Weekly Report
Loading ...
Support Center